AMD Advanced Micro Devices Inc

Previous close
$217.50
Est. 12 months change
+28.19%
Projected Price
$279.42

Profitability Metrics

Return on Equity (ROE)
7.17%
Return on Assets (ROA)
4.54%
Return on Invested Capital (ROIC)
6.34%
Weighted Average Cost of Capital (WACC)
16.12%
ROIC - WACC
-9.78%
Updated : 2026-04-03 18:22 ET

Valuation Metrics

P/E Ratio
82.71
Forward P/E
32.64
PEG Ratio
2.00
Debt Current Ratio
2.85

Growth & Cash Flow

Gross Margin
51.01%
Operating Margin
10.73%
FCF Margin
19.44%
TTM Revenue Growth
34.11%
Projected 12M EPS Growth
153.42%

Price Change

Price % from 50 SMA
2.77%
Price % from 200 SMA
10.47%
6 Months
28.14%
1 Year
111.25%
2 Years
21.71%
Click here to see the list of ETFs containing AMD as a top holding :AMD ETFs

Analysis

Company Overview

Advanced Micro Devices designs CPUs, GPUs, FPGAs, and adaptive SoCs targeting data centers, gaming, embedded, and client computing markets. Sector: Technology.

Overview

Advanced Micro Devices Inc (AMD) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Profitability & Capital Efficiency

On the question of capital productivity, ROIC is 6.34%, WACC is 16.12%, and the economic spread is -9.78%. On balance, the spread between returns and funding costs is negative — a dynamic that pressures intrinsic value unless operating performance improves. Supporting metrics show ROE at 7.17% and ROA at 4.54%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company that likely needs operating improvement before returns quality can be considered durable.

Valuation

Assessed on a multiple basis, trailing P/E of 82.71, forward P/E of 32.64, PEG of 2.00. The difference between trailing and forward multiples is significant, suggesting investors are paying today for earnings that have not yet been fully delivered. Growth-adjusted, the multiple is in an acceptable range — the company is neither pricing in perfection nor offering a meaningful valuation discount. The company carries a current ratio of 2.85, pointing to strong short-term financial health. Overall, the valuation setup reads as a balance between expected growth and execution risk, with liquidity acting as an important stabilizer if macro conditions become less favorable.

Margins & Cash Generation

The margin stack reads as follows: gross margin sits at 51.01%, operating margin at 10.73%, and free cash flow margin at 19.44%. The gross margin reading points to the company with solid but not outsized pricing power relative to direct costs. The company's operating margins leave limited room between gross profit and operating earnings — a sign of cost pressure. FCF margins are constructive here, reflecting the company that generate cash reliably after reinvestment requirements. The profile is not weak, but it is uneven enough that execution and cost control remain central to the forward case.

Growth & Forward Outlook

The forward view combines two signals: the estimated 12-month price change of 28.47%, where analyst assumptions support a moderate upside case if execution remains steady, while TTM revenue growth of 34.11% suggesting the company is collectively capturing meaningful market share or pricing power. The projected 12-month EPS growth rate of 153.4% is a standout component of the forward case — meaningful earnings expansion at this scale typically warrants attention from growth-oriented investors. One metric reflects operational reality, the other market expectation — both are useful inputs, but neither should be read in isolation. The interaction between revenue execution and analyst repricing will ultimately determine how closely realized returns track current expectations. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Buy

The overall evidence base is constructive, with more signals pointing up than down and no obvious structural impairment to the forward case.

This summary is based on publicly available quantitative data and is not intended as investment advice. Carefully consider your personal financial circumstances before making any decisions.